Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 14Active not recruiting 6Recruiting 4Withdrawn 2Unknown 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Hepatocellular 7Neoplasms 2Urologic Neoplasms 1Thyroid Neoplasms 1Sarcoma, Kaposi 1Hepatitis B 1GBM 1Endometrial Neoplasms 1Cholangiocarcinoma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Brain Neoplasms 1Advanced Hepatocellular Carcinoma 1Acrocephalosyndactylia 1

Interventions

Cisplatin 9pembrolizumab 7Radiosurgery 6Gemcitabine 6Paclitaxel 5Dexamethasone 5Taxes 4Carboplatin 4trametinib 3ibrutinib 3Surveys and Questionnaires 3Standard of Care 3Radiotherapy 3Nivolumab 3Magnetic Resonance Spectroscopy 3Lenalidomide 3Fluorouracil 3Erlotinib Hydrochloride 3Blood Specimen Collection 3Ascorbic Acid 3venetoclax 2veliparib 2tocilizumab 2pazopanib 2obinutuzumab 2naquotinib 2lenvatinib 2fludarabine 2enzalutamide 2Vemurafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Neoplasms × lenvatinib × Clear all
NCT06161558 2025-07-16

Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Withdrawn
Tumor-Agnostic

Neoplasms

NCT02846766 2018-08-02

Study of Lenvatinib in Patients With Advanced Cancer and Aberrations in FGF/FGFR Signaling

University of California, San Diego

Phase 2 Withdrawn

Acrocephalosyndactylia, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡